These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27939012)

  • 21. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
    Moody MA; Gao F; Gurley TC; Amos JD; Kumar A; Hora B; Marshall DJ; Whitesides JF; Xia SM; Parks R; Lloyd KE; Hwang KK; Lu X; Bonsignori M; Finzi A; Vandergrift NA; Alam SM; Ferrari G; Shen X; Tomaras GD; Kamanga G; Cohen MS; Sam NE; Kapiga S; Gray ES; Tumba NL; Morris L; Zolla-Pazner S; Gorny MK; Mascola JR; Hahn BH; Shaw GM; Sodroski JG; Liao HX; Montefiori DC; Hraber PT; Korber BT; Haynes BF
    Cell Host Microbe; 2015 Sep; 18(3):354-62. PubMed ID: 26355218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.
    Balasubramanian P; Kumar R; Williams C; Itri V; Wang S; Lu S; Hessell AJ; Haigwood NL; Sinangil F; Higgins KW; Liu L; Li L; Nyambi P; Gorny MK; Totrov M; Nadas A; Kong XP; Zolla-Pazner S; Hioe CE
    Vaccine; 2017 Mar; 35(10):1464-1473. PubMed ID: 28185743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.
    Totrov M; Jiang X; Kong XP; Cohen S; Krachmarov C; Salomon A; Williams C; Seaman MS; Abagyan R; Cardozo T; Gorny MK; Wang S; Lu S; Pinter A; Zolla-Pazner S
    Virology; 2010 Sep; 405(2):513-23. PubMed ID: 20663531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.
    Crooks ET; Almanza F; D'Addabbo A; Duggan E; Zhang J; Wagh K; Mou H; Allen JD; Thomas A; Osawa K; Korber BT; Tsybovsky Y; Cale E; Nolan J; Crispin M; Verkoczy LK; Binley JM
    PLoS Pathog; 2021 Oct; 17(10):e1009807. PubMed ID: 34679128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
    Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):245-51. PubMed ID: 8018385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
    Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
    Devash Y; Rusche JR; Nara PL
    Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
    Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
    Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.